Agilent Technologies to Collaborate with Spain’s Centre for Omic Sciences
News Oct 31, 2012
The Centre for Omic Sciences, or COS, was established by the Rovira i Virgili University, in collaboration with the Technological Centre of Nutrition and Health. COS opened in September and is equipped with the latest instrumentation from Agilent, including the 6550 iFunnel Quadrupole Time-of-Flight LC/MS, 7200 Quadrupole Time-of-Flight GC/MS, 6490 iFunnel Triple Quadrupole LC/MS, Bravo automated liquid handling systems, and the SureScan DNA microarray scanner, software, consumables and services.
"Agilent is an ideal partner because many of their workflow solutions are an excellent fit for our approach to integrating data from different omics techniques,” said Oscar Yanes, principal investigator at the COS. “The ability to generate data using mostly Agilent instrumentation will facilitate the interpretation and integration of results from the different techniques.”
The COS will also serve as a center of excellence where Agilent will demonstrate integrated biology workflows to customers in such disciplines as genomics, proteomics, transcriptomics, lipidomics and metabolomics in search of biological breakthroughs.
"This is a very strategic association between two organizations with similar goals,” said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. “Both are committed to driving advances in medicine by developing better ways to integrate data from multiple biological disciplines. We share this vision.”
The COS will perform its collaborative research programs and services with the Technological Centre of Nutrition and Health and with private companies and research groups that take a special interest in the fields of diabetes and metabolic diseases, nutrition and health, and other biomedical research areas.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE